Aldeyra Therapeutics Soars 20.7% Intraday: What’s Fueling the Surge?

Summary
• Aldeyra Therapeutics (ALDX) surges 20.7% in a single session to trade at $2.185 by 4:34 PM
• Intraday high hits $2.26, nearly 130% above its intraday low at $1.8245
• Options trading activity spikes, with high turnover and leverage ratios in the $2 strike price calls

Aldeyra Therapeutics is capturing market attention after a dramatic intraday price jump. The biotech stock, already trading far below its 52-week high of $6.55, now faces a critical inflection point. With a strong volume-to-open interest ratio and rising call options activity, the market is betting on a short-term reversal. Here's how the fundamentals and options action are shaping this sudden move.

Options Buying and Short-Term Sentiment Spark Volatility
The surge in Aldeyra Therapeutics is primarily fueled by heavy call option buying in the $2 strike price contracts, especially those with near-term expirations. Despite a broader bearish technical backdrop — including a short-term and long-term bearish trend, a negative MACD (-0.829), and an RSI of 21.09 suggesting oversold conditions — the options market is showing aggressive positioning. High leverage ratios (up to 8.70%) and strong turnover in the $2 call options indicate institutional or savvy retail traders are anticipating a short-term bounce. The price has also moved well above the lower Bollinger Band and below all key moving averages, creating a high-risk, high-reward environment as the stock attempts to re-engage with the $2 psychological level.

Pharma Sector Slides as Pfizer Drags Down, Highlighting AIDX Outperformance
While Aldeyra Therapeutics is rallying, the broader pharmaceutical sector is underperforming. Sector leader Pfizer (PFE) is down by 1.038% intraday, reflecting broader caution in the sector due to regulatory uncertainties and pricing pressures. Aldeyra’s sharp counter-movement suggests the stock is trading on its own fundamentals or options-driven positioning rather than sector-wide dynamics. This divergence underscores the importance of options liquidity and trader psychology in small-cap biotech plays, where news flow and technical triggers often dominate over sector performance.

High-Leverage Call Options and Key Technicals Signal Short-Term Bullish Setup
• MACD (-0.829, -0.437 signal) is bearish but RSI (21.09) is in oversold territory
• 200-day MA at $4.86 (far above current price), 50-day MA absent due to long-term bear
• Bollinger Bands show current price at 1.39 (lower band), indicating extreme volatility

ALDX is in a textbook low-price, high-volatility scenario where aggressive bulls can use leveraged call options to bet on a short-term rebound. The $2 strike price call options (ALDX20260417C2 and ALO20260402C2) are the most liquid and offer high leverage and sensitivity to price swings. Here's a breakdown of two top options:

• Bold( ALDX20260417C2 ): Call Option, Strike $2, Expiration 2026-04-17, IV 159.90%, Leverage 4.83%, Delta 0.66, Theta -0.0082, Gamma 0.394, Turnover 6237
– High IV reflects market anticipation of volatility; Delta of 0.66 suggests moderate sensitivity to stock price movement; Gamma of 0.394 indicates strong price responsiveness
– A 5% upside from $2.185 (to $2.29) would yield a payoff of $0.29 per share, translating to a 36% gain on the option
– This option is ideal for those expecting a sharp, near-term rebound as AIDX approaches key resistance at $2.50

• Bold( ALDX20260402C2 ): Call Option, Strike $2, Expiration 2026-04-02, IV 30.00%, Leverage 6.40%, Delta 0.95, Theta -0.0081, Gamma 0.885, Turnover 3206
– High Delta (0.95) indicates near one-to-one price tracking, suitable for strong bullish bets; High Gamma (0.885) means it's highly sensitive to price movement
– A 5% upside scenario yields $0.29 payoff, which could translate to a 45% gain due to high leverage
– This is a short-term, high-conviction play for traders expecting immediate strength as the stock breaks above $2.20

Aggressive bulls may consider Bold( ALDX20260417C2 ) or Bold( ALDX20260402C2 ) into a clear breakout above $2.25, with a stop-loss below $2.10 to manage risk. The high volatility and gamma readings suggest these contracts offer a compelling risk-reward profile if the price can hold above the 52-week low and retest the $2.50 area.

Backtest Aldeyra Therapeutics Stock Performance
The backtest of ALDX's performance after a 21% intraday increase from 2022 to now shows favorable results. The 3-Day win rate is 52.88%, the 10-Day win rate is 55.76%, and the 30-Day win rate is 60.08%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 14.12%, which occurred on day 58, suggesting that ALDX can deliver significant gains following the intraday surge.

Short-Term Bulls Target $2.25 Breakout: What to Watch Next
The move in Aldeyra Therapeutics is driven by call options buying rather than fundamental news, making it a technical trade that hinges on liquidity and sentiment. While the broader biotech sector remains under pressure — as shown by Pfizer's negative intraday performance — AIDX’s short-term bounce is creating a pocket of optimism. Investors should watch for a breakout above $2.25 to confirm the reversal, with a key support level at $2.10. If the price holds and the RSI recovers above 30, the stock may test $2.50 next. Aggressive option traders are advised to act quickly on the AIDX20260417C2 and AIDX20260402C2 contracts. Watch for $2.25 break and $2.10 breakdown to determine next steps.